Tees, Esk and Wear Valleys NHS Foundation Trust

PRESCRIBING GUIDELINES FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN & YOUNG PEOPLE

Complete baseline ADHD assessment & offer medication to children aged 5 years and over* and young people if:

- Their ADHD symptoms are still causing persistent, significant impairment in at least one domain after environmental modifications have been implemented and reviewed
- They and their parents/carers have discussed information about ADHD

For pre-treatment assessment & ongoing monitoring click here & print patient information leaflets from Choice and medication website

* N/B drug treatments not licensed in children under 6 years

Prescribe methylphenidate immediate release, Or Prescribe a methylphenidate modified release preparation for: convenience, increased adherence, reduced stigma at school or better pharmacokinetics (see overleaf for options) Start at the appropriate dose using the current BNFC & increase dose as appropriate to the minimum effective dose. If 6 week trial at an adequate dose and not Effective management of symptoms derived enough benefit in terms of reduced with minimal side effects - continue ADHD symptoms and associated with minimum effective dose and impairments - stop methylphenidate transfer prescribing to primary care in line with shared care guidelines Prescribe lisdexamfetamine² at the recommended dose in the current BNFC. Review at least annually once stable Switch to dexamfetamine if responds to If ineffective treatment (not responded to 6 lisdexamfetamine but week trial of adequate doses) or intolerable can't tolerate longer side effects, having considered alternative effect profile preparations - stop lisdexamfetamine (dexamfetamine) \mathbf{V} Consider adjunctive therapies only with Prescribe atomoxetine at the recommended dose in advice from tertiary service: e.g. atypical the current BNFC. If effective, review every at least antipsychotics (co-existing pervasive annually or Prescribe guanfacine³ at the appropriate aggression, rages or irritability) or clonidine dose. If effective, assess every 3 months (during first (sleep disturbance, rages or tics) (both year), every 6 months thereafter. unlicensed)1

PRESCRIBING ADVICE FOR ALL PATIENTS

All medication is licensed for children over 6 years unless otherwise stated. Prior to initiation check the BNF or relevant product information for any cautions or contra-indications to the chosen treatment. Review diagnosis and co-morbidities if expected response to treatment is not observed, especially when changing type of drug treatment (stimulant to non-stimulant, and vice versa). Seek second opinion or refer to tertiary services any child or young person unresponsive to one or more stimulants or one non-stimulant

Consider a drug holiday during school holidays to minimise adverse effects. Consider shared care once patient is clinically stable.

- 1. For advice on appropriate dosages or conversion, please contact a member of the Trust pharmacy team
- 2. Capsules may be opened and the capsule contents sprinkled onto a small amount (tablespoon) of apple sauce or yoghurt and given immediately, and not stored for future use.
- 3. Consider guanfacine before atomoxetine & other stimulants (i.e. 2nd line) in children who lose significant weight on methylphenidate

Title	Prescribing Guidelines for ADHD in Children & Young People					
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, amended 24/11/22			
Protocol Number	PHARM-0077-v3.1	Date of Review	1 st June 2024			



PRESCRIBING GUIDELINES FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN & YOUNG PEOPLE

AVAILABLE METHYLPHENIDATE MODIFIED-RELEASE PREPARATIONS (see guidance here for more information on relative pharmacokinetics)

Brand	Available strengths	Description	Release profile	NHS indicative price (30)	Brand	Available strengths	Description	Release profile	NHS indicative price (30)
Preparations with 22% immediate-release component and 78% extended-release components				se	Preparations with 30% immediate-release component and 70% extended-release component				
Delmosart tablets	18 mg	Yellow capsule shape tablet		£15.57	Equasym XL capsules ²	10 mg	Dark green opaque capsule	Immediate-release component gives a maximum plasma	£25.00
	27 mg	Grey capsule shape tablet		£18.39		20 mg	Blue opaque capsule	concentration after 1.5 hours; extended-release component	£30.00
	36 mg	White capsule shape tablet		£21.23		30 mg	Reddish brown opaque capsule	gives a second peak after 6 hours. Duration of action up to 8 hours.	£35.00
	54 mg	Red capsule shape tablet		£36.79	Preparations with 50% immediate-release component and 50% extended-release component				e
Xenidate XL	18 mg	Yellow round tablet	1	£15.57	Medikinet XL	5 mg	White capsule	Immediate-release component	£24.04
tablets	27 mg	Yellow oblong tablet	1	£18.39	capsules ²	10 mg	Lilac/ white capsule	gives a rapid peak plasma	£24.04
	36 mg	White oblong tablet		£21.21	E21.21 Take with or	20 mg	Lilac capsule	concentration; extended-	£28.86
	54 mg	Red oblong tablet	Immediate-release component gives a maximum plasma	£36.79	after breakfast	30 mg	Purple/ light grey capsule	release component gives a second peak after 3-4 hours.	£33.66
Xaggitin XL tablets	18 mg	Yellow capsule shape tablet	concentration after 1-2 hours; extended-release component	£15.58		40 mg	Purple/ grey capsule	Duration of action up to 8 hours.	£57.72
	27 mg	Grey capsule shape tablet	gives a second peak after 6-8 hours.	£18.40		50 mg	Violet/dark violet capsule		£62.52
	36 mg	White capsule shape tablet	Duration of action up to 12 hours.	£21.22		60 mg	Dark violet capsule		£67.32
	54 mg	Red/brown capsule shape tablet		£36.80	Ritalin XL capsules ²	10 mg	Brown opaque capsule	Immediate-release component gives a rapid peak plasma	£23.92
Concerta XL tablets	18 mg	Yellow capsule shape tablet		£31.19	Can be taken with or without	20 mg	White opaque capsule	concentration at 1-2 hours; extended-release component	£28.72
	27 mg	Grey capsule shape tablet		£36.81	food	30 mg	Yellow opaque capsule	gives a second peak after 4 hours.	£33.49
	36 mg	White capsule shape tablet		£42.45		40 mg	Brown opaque capsule	Duration of action up to 8 hours.	£57.43
	54 mg	Red capsule shape tablet		£73.62		60 mg	Brown and yellow opaque capsule		£66.98
Matoride XL	18 mg	Yellow round tablet	1	£15.58					
tablets	36 mg	White round tablet]	£21.22					
	54 mg	Pink round tablet		£36.80					

Title	Prescribing Guidelines for ADHD in Children & Young People					
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, amended 24/11/22			
Protocol Number	PHARM-0077-v3.1	Date of Review	1 st June 2024			